Angiotensin receptor blockers: Evidence for preserving target organs

Clinical Cardiology

Volumn 24, Issue 3, 2001, Pages 183-190

  Carson, Peter ^a   Giles, Thomas ^b   Higginbotham, Michael ^c   Hollenberg, Norman ^d   Kannel, William ^e   Siragy, Helmy M ^f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Louisiana State Iniversity Medical Center   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin receptor subtypes; Angiotensin converting enzylne; Heart failure; Hypertension; Myocardial hypertrophy; Myocardial infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN POTASSIUM; PLACEBO; RECEPTOR SUBTYPE; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TARGET ORGAN;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0035112289     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960240303     Document Type: Review

References (67)

1. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2. Factors associated with noncompliance of patients taking antihypertensive medications
3. Intermittent blood pressure control: Potential consequences for outcome
4. Effect of bradykinin-receptor blockade on the response to angiotensin-converting -enzyme inhibitor in normotensive and hypertensive subjects
5. Does blockade of angiotensin II receptors offer clinical benefits over inhibition of angiotensin-converting enzyme?
6. Prevention of renovascular and cardiac pathophysiological changes in hypertension by angiotensin II type I receptor antisense gene therapy
7. 1 receptor blockers
8. 2 receptor protein in rats with angiotensin-dependent hypertension
9. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors
10. 2 receptor: Fact, fancy and fantasy
11. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis
12. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT 1 receptor-mediated pressor and chronotropic effects
13. Angiotensin II receptor antagonists in hypertension
14. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition
15. Chymase: Its pathophysiological roles and inhibitors
16. Angiotensin I converting enzyme and chymase in cardio-vascular tissues
17. Pathways for angiotensin Il generation in intact human tissue. Evidence from comparative pharmacological interruption of the renin system
18. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension
19. Epidemiology of risk factor clustering in elevated blood pressure
20. Pathophysiology of heart failure
21. Physiologic versus pathologic hypertrophy and the pressure-overloaded myocardium
22. Angiotensin and cell growth: A link to cardiovascular hypertrophy?
23. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype
24. Renin-angiotensin system, hypertrophy and gene expression in cardiac myocytes
25. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies
26. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies
27. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy
28. Influence of the angiotensin Il antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension
29. Myocardial characteristics of pressure overload hypertrophy. A structural and functional study
30. Progression of heart failure: A role for interstitial fibrosis
31. What is the relevance of apoptosis to the myocardium?
32. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators
33. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators
34. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
35. Effect of enalapril on mortality, and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
36. Losartan in heart failure. Hemodynamic effects and tolerability
37. Valsartan in heart failure patients previously untreated with an ACE inhibiton
38. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure
39. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
40. Angiotensin II-forming pathways in normal and failing human hearts
41. 1 receptor inhibition, and combination therapy with pacing induced heart failure: Effects on left ventricular performance and regional blood flow patterns
42. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure. I. Effects on left ventricular performance and neurohormonal systems
43. Augmented short- and long-term liemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure
44. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced bean failure. II. Effects on myocyte contractile processes
45. Angiotensin II-receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure
46. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure
47. Role of catecholamines and sympathetic activation as a risk factor for coronary artery disease
48. Pathophysiological aspects of the reninangiotensin -aldosterone system in acute myocardial infarction
49. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: Development of a predictive model
50. The Survival and Ventricular Enlargement (SAVE) study: Rationale and perspective
51. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril
52. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: Effect of captopril
53. A clinical trial of the angiotensin-converting -enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
54. Effect of ramipril on mortality, and morbidity, of survivors of acute myocardial infarction with clinical evidence of heart failure
55. Comparison of effects of losartan and capropril on mortality, in patients after acute myocardial infarction: The OPTIMAAL trial design
56. Incidence and prevalence of ESRD
57. Blood pressure and end-stage renal disease in men
58. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study
59. Renal protection and antihypertensive drugs: Current status
60. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy
61. Valsartan (Diovan®): Effect on microalbuminuria in patients with type Il diabetes and nephropathy
62. 2 receptor in a renal wrap hypertension model
63. 2) angiotensin receptor mediates renal production of nitric oxide in conscious rats
64. 2 production in conscious rats
65. 2) angiotensin receptor
66. Angiotensin-II receptor antagonists: Their place in therapy